Safety Data on the Pola-BR Regimen in R/R DLBCL
Gilles Salles, MD, PhD, explains data on the adverse events seen with the pola-BR regimen in R/R DLBCL during the GO29365 clinical trial.
Case: A 51-Year-Old Woman with Diffuse Large B-Cell Lymphoma (DLBCL)
Case Description
A 51-year-old woman presented with fatigue and back pain that worsened in the past 3 months
History of mild hypertension (controlled with medication)
Physical exam: Left posterior cervical node, 1.7-cm; left anterior cervical node, 2.9-cm; right supraclavicular node, 2.5-cm
ECOG PS 0
CT scan: multiple enlarged mesenteric and retroperitoneal nodes, largest measuring 5.3 x 3.1 cm
Biopsy confirmed diffuse large B-cell lymphoma, IHC positive for:
CD20
BCL-6, MUM1
BCL-2 (50% of cells)
MYC (>90% of cells)
Ki67 83%
FISH: negative for MYC rearrangement/chromosomal abnormality
Normal CBC and LDH
Initial Treatment
Patient received 6 cycles of RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
Back pain and fatigue resolved
Post-treatment PET scan results demonstrated a CR (Deauville score 2)
Patient was scheduled for follow-up visits at 3-month intervals
Follow-up Notes/Labs 9 Months After Completion of First-Line Therapy
Patient complained of increased fatigue and back pain, emergent fever and night sweats
A palpable lymph node in right groin was discovered on physical examination
PET and CT scans: new left inguinal lymph node, increase in size of residual node, as well as multiple metabolically active lesions in lymph nodes of the retroperitoneum, abdomen, and pelvis
Biopsy: DLBCL, non-germinal center B-cell
Second-Line Treatment
Patient was referred to transplant center
Patient received salvage RICE (rituximab, ifosfamide, carboplatin, etoposide)
PET-CT scan results after 2 cycles: Deauville score 5
Third-Line Treatment
When discussing next steps, the patient declined ASCT and CAR T-cell therapy due to the time commitment and travel required for administration, as well as financial concerns
The patient received polatuzumab vedotin/bendamustine/rituximab as 3rd-line treatment
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Later-Line CD19 and Bispecific Therapies Considered After CAR T
October 1st 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Read More
Participants Discuss LOTIS-2 Data Based on Patient Case of DLBCL
September 16th 2024During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma
September 11th 2024The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.
Read More
